Physician profile
Thomas E James
NPI 1285691196
$2,659.76
in general payments reported to CMS, 2019-2025
21 companies · $921 in 2025
The $921 reported for 2025 was more than what 84% of Neuromusculoskeletal Medicine, Sports Medicine providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.24 · 2020: $174 · 2021: $90.89 · 2022: $439 · 2023: $330 · 2024: $680 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $646.15 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $438.88 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $407.47 | 2021-2025 | |
| Corcept Therapeutics | $233.52 | 2025 | Korlym |
| Janssen Pharmaceuticals, INC | $133.15 | 2020-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.54 | 2022-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $96.90 | 2024-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $94.69 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $84.55 | 2023-2024 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $75.49 | 2024-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $63.20 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $61.47 | 2023-2024 | Voquezna |
| Abbott Laboratories | $39.29 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $33.78 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.52 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $24.50 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $24.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.39 | 2024 | Trintellix |
| Inspire Medical Systems, INC. | $17.39 | 2025 | Inspire |
| Amarin Pharma, INC. | $15.46 | 2020 | |
| Astellas Pharma US INC | $12.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.